The Food and Drug Administration (FDA) commissioner's plan to expedite drug reviews has sparked concern among agency staff and experts. The program, known as the National Priority Voucher, promises accelerated approval in as little as one month for medicines deemed to support U.S. national interests. However, this approach has raised questions about legal authority, ethical standards, and scientific integrity, especially as it deviates from traditional FDA review processes.
Marty Makary's program has caused anxiety and confusion among staff already affected by layoffs, buyouts, and leadership changes. The lack of transparency in the voucher program's workings has led to concerns about political interference in drug approvals, a departure from the objective standards and procedures typically followed by the FDA.
Critics argue that the accelerated review process may compromise the safety and effectiveness of new medicines, as it does not adhere to the usual scientific review standards. Dr. Aaron Kesselheim highlights the impossibility of conducting a thorough review in such a short time frame, citing the need for detailed scientific scrutiny.
The program's popularity at the White House has been noted, with pricing concessions often accompanied by FDA vouchers for drugmakers. This has led to concerns about the potential for political influence in drug approvals, as evidenced by the scramble to vet vouchers for Eli Lilly and Novo Nordisk in time for a Trump news conference.
The lack of codified rules and regulations for the voucher program has further complicated matters. The absence of a formal application process and the involvement of senior agency leaders in voucher decisions have created confusion and legal questions.
Despite the concerns, some argue that the commissioner has the authority to reorganize drug review processes under federal law. However, the program's short-term nature and susceptibility to political changes are highlighted as potential drawbacks.
The expansion of the voucher program to 18 awarded vouchers and more under consideration has put additional pressure on the FDA's drug center, which has already seen a significant staff turnover. The program's future remains uncertain, with experts suggesting it may not endure beyond the current administration.
